不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
我如何治疗弥漫大 B 细胞淋巴瘤
英文原题：How I treat diffuse large B-cell lymphoma.
查看英文原题
How I treat diffuse large B-cell lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
弥漫大 B 细胞淋巴瘤（DLBCL）初诊时通常采用以治愈为目标的化学免疫治疗。新药已改善高危患者一线及复发阶段的预后，更准确的预后工具则使低危患者能够接受强度较低的治疗，同时保持良好预后。本文总结我们根据风险特征及其他临床常见挑战，处理 DLBCL 一线患者的方案。对于低危患者且中期正电子发射断层显像阴性，我们建议缩短化学免疫治疗疗程。对于疾病风险较高者，含 polatuzumab vedotin 的新型联合治疗已获批，可作为新选择。我们还讨论后续中枢神经系统受累高风险患者、腿型淋巴瘤患者及严重合并症患者的处理方法。
展开英文摘要原文
Diffuse large B-cell lymphoma (DLBCL) is usually treated with chemoimmunotherapy in curative intention at initial diagnosis. Novel agents have improved the prognosis of high-risk patients in the front-line and relapsed setting and more accurate prognostic tools enable less intensive treatment for low-risk patients, while maintaining their good prognosis.
Here, we summarize our approach to DLBCL patients in the first-line setting according to their risk profile and other common challenges in clinical practice.
We recommend an abbreviated course of chemoimmunotherapy in low-risk patients and a negative interim positron emission tomography. For patients with higher-risk disease, a new combination treatment with polatuzumab vedotin has been approved and is a new option in these patients.
We also discuss our approach to patients with high risk for subsequent central nervous system involvement, with leg-type lymphoma or with severe comorbidities.
论文信息
- 作者
- Melchardt T、Egle A、Greil R
- 第一作者单位
- IIIrd Medical Department at the Paracelsus Medical University Salzburg, Cancer Center, Salzburg; Salzburg Cancer Research Institute, Salzburg; Austrian Group for Medical Tumor Therapy (AGMT), Salzburg; Cancer Cluster, Salzburg, Austria.Austria
- 通讯作者单位
- IIIrd Medical Department at the Paracelsus Medical University Salzburg, Cancer Center, Salzburg; Salzburg Cancer Research Institute, Salzburg; Austrian Group for Medical Tumor Therapy (AGMT), Salzburg; Cancer Cluster, Salzburg, Austria. Electronic address: r.greil@salk.at.Austria
- 文献类型
- 综述
- 期刊
- ESMO open2023 Feb
- 原文标识
- PubMed 36634531 · DOI 10.1016/j.esmoop.2022.100750
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →